Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
A narrower net loss accompanied higher operating expenses, while current cash is expected to support planned operations into 2028.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC) reported a narrower third-quarter net loss as it advanced Descartes-08 toward a pivotal myasthenia gravis readout. Net loss was $11.472 million, or $0.38 per share, versus $35.902 million, or $1.38 per share, a year earlier. Revenue fell to zero from $452,000, while operating loss widened to $25.001 million from $21.066 million.
Cash, cash equivalents and restricted cash totaled $124.7 million; the company expects funding into 2028. Cartesian expects Phase 3 AURORA data in 1Q27 and plans a biologics license application in mid-2027. Five retreated patients showed a mean 6.6-point improvement in a daily-function score at Month 12, with no new safety signals. Data from a subset of Phase 2 TRITON patients and the Phase 1/2 HELIOS pediatric trial are expected in 1H27. The WestGene in vivo cell-therapy partnership remains in preclinical development.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointK2 HealthVentures financing provided an initial $50 million non-dilutive tranche. 24% of market cap
- Moderate pointThird-quarter net loss narrowed to $11.472 million from $35.902 million; loss per share fell to $0.38 from $1.38.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash resources of $124.7 million are expected to fund planned operations, including AURORA completion, into 2028.
- Moderate pointAt-the-market offering raised $22.8 million year to date after commissions and expenses. 11% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.AURORA Phase 3 data are expected in 1Q27; Cartesian plans a biologics license application in mid-2027.
11 minor points
- Minor pointNine-month net loss narrowed to $34.885 million from $37.726 million; loss per share fell to $1.21 from $1.45.
- Minor pointRetreatment produced a mean 6.6 (±4.2)-point reduction in the myasthenia daily-function score at Month 12.
- Minor pointAll five retreated patients achieved clinically meaningful improvements on both myasthenia assessment scales.
- Minor pointFour of five patients maintained clinically meaningful daily-function improvement through Month 12 after retreatment.
- Minor pointDescartes-08 retreatment showed no new safety signals.
- Minor point. Forward-looking: it has not happened yet and may not happen.TRITON subset data are expected in 1H27 to inform a potential pivotal myositis trial.
- Minor point. Forward-looking: it has not happened yet and may not happen.HELIOS pediatric trial enrollment continues, with data expected in 1H27.
- Minor pointWestGene partnership testing generated CAR-T cells in a dose-dependent manner in laboratory studies.
- Minor pointMedical affairs and commercial teams have expanded to prepare for a potential launch.
- Minor pointThird-quarter contingent-value-rights remeasurement produced a $10.7 million gain, versus a $16.9 million loss a year earlier.
- Minor pointNine-month contingent-value-rights remeasurement gain rose to $46.1 million from $18.746 million.
Negative
- Major pointLong-term debt, net, reached $50.220 million at September 30, versus zero at December 31, 2025.
- Moderate pointNine-month operating loss widened to $80.655 million from $64.766 million.
- Moderate pointNine-month research and development expenses rose to $55.517 million from $43.345 million.
- Moderate pointAt-the-market share issuance that raised $22.8 million year to date diluted existing holders. 11% of market cap
- Minor pointThird-quarter revenue fell to zero from $452,000; nine-month revenue fell to $78,000 from $1.850 million.
11 minor points
- Minor pointThird-quarter operating loss widened to $25.001 million from $21.066 million.
- Minor pointThird-quarter research and development expenses rose to $15.623 million from $13.802 million.
- Minor pointThird-quarter general and administrative expenses rose to $9.378 million from $7.716 million.
- Minor pointNine-month general and administrative expenses rose to $25.216 million from $23.271 million.
- Minor pointThird-quarter interest expense reached $1.991 million, versus zero; nine-month expense reached $2.843 million, versus zero.
- Minor pointThird-quarter interest income declined to $1.202 million from $1.548 million.
- Minor pointNine-month interest income declined to $3.331 million from $5.311 million.
- Minor pointCommon shares outstanding increased to 30,487,384 from 26,011,106 at December 31, 2025.
- Minor pointStockholders’ deficit widened to $130.467 million from $126.240 million at December 31, 2025.
- Minor pointRetreatment evidence covered only five patients whose symptoms returned after 12 months of follow-up.
- Minor point. Forward-looking: it has not happened yet and may not happen.WestGene program clinical development is planned after completion of preclinical testing.
News Explained
At
Key Figures
- Cash, cash equivalents and restricted cash
- $124.7 million
- As of September 30, 2026
- Cash runway
- Into 2028
- Expected support for planned operations
- MG-ADL reduction
- 6.6 (±4.2) points
- Mean reduction from baseline at Month 12 after retreatment
- Retreatment analysis
- 5 patients
- Patients with MG included in the analysis
- Sustained MG-ADL reduction
- 4 of 5 patients
- Maintained clinically meaningful reduction through Month 12
- Research and development expenses
- $15.6 million vs. $13.8 million
- Three months ended September 30, 2026 vs. 2025
- General and administrative expenses
- $9.4 million vs. $7.7 million
- Three months ended September 30, 2026 vs. 2025
- Net loss
- $11.5 million vs. $35.9 million
- Three months ended September 30, 2026 vs. 2025
Previous Earnings Reports
-
Reported $149.3 million cash and maintained operations runway into 2028.
-
Reported $35.9 million quarterly net loss versus $24.2 million a year earlier.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics license application regulatory
car-t technical
mg-adl medical
at the market offering program financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027
Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG Activities of Daily Living (MG-ADL) reduction from baseline at Month 12 with no new safety signals
Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continue to progress, with data from both trials expected in 1H27
In vivo CAR-T program, in partnership with WestGene BioPharma, continues to advance
Approximately
FREDERICK, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026, and outlined recent business updates.
“With Phase 3 AURORA data expected in the first quarter of 2027, our focus this quarter remains on execution, both in the clinic and in preparing the organization for a commercial launch,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “Ahead of our anticipated BLA submission in mid-2027, we have expanded our medical affairs and commercial teams to drive launch readiness. With larger teams on the ground now, we are excited by the opportunity to expand awareness of Descartes-08’s differentiation, particularly on the back of the retreatment data we presented in September which continued to demonstrate deep and durable responses with a consistent safety profile, all with outpatient administration and no preconditioning chemotherapy. We believe this profile has the potential to meaningfully change how MG is treated. Beyond MG, we look forward to data from our TRITON and HELIOS trials expected in 2027 as we work to bring Descartes-08 to more patients with autoimmune diseases.”
Pipeline Progress and Anticipated Milestones
- Phase 3 AURORA Trial of Descartes-08 in Participants with MG Advances Towards Expected Data Readout in 1Q27, with BLA Planned for Mid-2027. The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08, Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 patients with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.
- Announced Retreatment Data for Descartes-08 Highlights Deep and Durable Responses in Patients with MG. In September 2026, Cartesian presented additional retreatment data at the Myasthenia Gravis Foundation of America Scientific Session of the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. The analysis included five patients with MG who completed a full course of Descartes-08 in the Phase 2 portion of the trial and whose symptoms returned after 12 months of follow-up. Patients were retreated a median of 16.6 months following completion of the initial course. At Month 12 following retreatment, patients achieved a mean MG-ADL reduction of 6.6 (±4.2) points from baseline. All five retreated patients experienced a clinically meaningful reduction across MG Composite (MGC) (≥3-point reduction) and MG-ADL scores (≥2-point reduction), and four of five patients maintained clinically meaningful MG-ADL reduction through Month 12. Consistent safety data observed to date supports potential retreatment of Descartes-08 following recurrence of MG symptoms, as clinical benefit was observed with no new safety signals.
- Phase 2 TRITON Trial in Myositis Remains on Track with Data from Subset of Patients Expected in 1H27 to Inform Path Forward to Pivotal Trial. The randomized, double-blind, placebo-controlled Phase 2 TRITON trial in myositis is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. The primary endpoint is to assess the safety and efficacy of Descartes-08 compared to placebo added to standard of care in participants with myositis. The Company plans to evaluate a subset of patients from the trial to determine the potential path to a pivotal trial in myositis.
- Phase 1/2 HELIOS Pediatric Trial of Descartes-08 in Autoimmune Diseases, Including JDM, Continues to Progress with Data Expected in 1H27. Enrollment remains ongoing in the Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including JDM. JDM is a rare pediatric autoimmune disorder marked by pathognomonic skin rash and muscle inflammation affecting multiple organ systems. The U.S. Food and Drug Administration (FDA) previously granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of JDM.
- In Vivo CAR-T Program with WestGene Continues to Advance Through Preclinical Development with In Vitro Data Supporting WestGene’s tLNP Delivery Approach. Cartesian’s previously announced partnership with WestGene continues to progress through preclinical development. To date, in vitro testing has shown that WestGene’s targeted lipid nanoparticles (tLNPs) generated CAR-T cells in a dose-dependent manner, supporting the tLNP delivery approach. Upon completion of preclinical testing, Cartesian plans to move the program into clinical development.
Third Quarter 2026 Financial Results
- Cash, cash equivalents and restricted cash as of September 30, 2026 was
$124.7 million , inclusive of the initial$50 million tranche of non-dilutive financing from K2 HealthVentures (K2HV) and$22.8 million raised year to date after commissions and expenses through the Company’s at the market offering program. The Company’s current cash resources on hand are expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial, into 2028. - Research and development expenses were
$15.6 million for the three months ended September 30, 2026, compared to$13.8 million for the three months ended September 30, 2025. The increase was primarily a result of increased expenses associated with the ongoing Phase 3 AURORA trial, coupled with expenses for Descartes-08 in dermatomyositis, primarily related to the expense for the ongoing Phase 2 TRITON trial. This increase was partially offset by a decrease in expenses for early stage programs. - General and administrative expenses were
$9.4 million for the three months ended September 30, 2026, compared to$7.7 million for the three months ended September 30, 2025. The increase was primarily the result of higher professional and consulting fees and employee-related expenses. - Net loss was
$11.5 million , or$0.38 net loss per share allocable to common stockholders (basic), for the three months ended September 30, 2026, compared to net loss of$35.9 million , or$1.38 net loss per share allocable to common stockholders (basic), for the three months ended September 30, 2025.
About Descartes-08
Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome. In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of JDM.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Forward Looking Statements
Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the Company’s expected cash resources and cash runway, the availability and use of funds under the Company’s credit facility with K2HV, statements regarding the partnership and strategic licensing agreement between the Company and WestGene and the ability of the Company and WestGene to develop therapies, treat disease, extend mRNA payloads into in vivo delivery, the integration and complementary nature of the Company’s product candidates and WestGene’s lipid nanoparticles platform, the speed and efficiency of the development pathway for collaboration products between the Company and WestGene, the ability of the Company and its partnership with WestGene to generate clinical proof-of-concept data across multiple programs in several disease states, the ability of the Company and its partnership with WestGene to advance multiple internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE and the speed at which these constructs and TCE are developed, the ability of the Company’s product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, or any of the Company’s other product candidates to treat MG, juvenile MG, myositis, JDM, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in MG, the ongoing Phase 2 TRITON trial of Descartes-08 in myositis, and the ongoing Phase 1/2 HELIOS pediatric trial of Descartes-08 in autoimmune diseases, including JDM, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the Company’s ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to enter into and maintain potential collaborations or partnerships, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company’s clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, political uncertainty, the Company’s reliance on third parties to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company’s common stock, risks related to geopolitical conflicts, pandemics, and macroeconomic impacts, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.
| Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Balance Sheets (Amounts in thousands, except share data and par value) | |||||||
| September 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| (unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 122,975 | $ | 125,139 | |||
| Accounts receivable | 52 | 1,115 | |||||
| Prepaid expenses and other current assets | 8,471 | 3,022 | |||||
| Total current assets | 131,498 | 129,276 | |||||
| Property and equipment, net | 10,731 | 12,185 | |||||
| Right-of-use assets, net | 4,879 | 5,601 | |||||
| In-process research and development asset | 93,900 | 93,900 | |||||
| Goodwill | 48,163 | 48,163 | |||||
| Long-term restricted cash | 1,735 | 1,735 | |||||
| Long-term prepaid expenses and other assets | 3,399 | 5,551 | |||||
| Total assets | $ | 294,305 | $ | 296,411 | |||
| Liabilities and stockholders’ deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 105 | $ | 1,288 | |||
| Accrued expenses and other current liabilities | 11,383 | 9,498 | |||||
| Lease liabilities | 4,210 | 4,151 | |||||
| Total current liabilities | 15,698 | 14,937 | |||||
| Lease liabilities, net of current portion | 5,906 | 8,525 | |||||
| Warrant liability, net of current portion | — | 141 | |||||
| Long-term debt, net | 50,220 | — | |||||
| Contingent value rights liability | 346,000 | 392,100 | |||||
| Deferred tax liabilities, net | 6,948 | 6,948 | |||||
| Total liabilities | 424,772 | 422,651 | |||||
| Stockholders’ deficit: | |||||||
| Series A Preferred Stock, September 30, 2026 and December 31, 2025, respectively; 98,050.372 and 120,790.402 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | — | — | |||||
| Series B Preferred Stock, and December 31, 2025; 437,927 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — | |||||
| Preferred stock, September 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — | |||||
| Common stock, December 31, 2025; 30,487,384 and 26,011,106 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 3 | 3 | |||||
| Additional paid-in capital | 731,409 | 700,706 | |||||
| Accumulated deficit | (857,258 | ) | (822,373 | ) | |||
| Accumulated other comprehensive loss | (4,621 | ) | (4,576 | ) | |||
| Total stockholders’ deficit | (130,467 | ) | (126,240 | ) | |||
| Total liabilities and stockholders’ deficit | $ | 294,305 | $ | 296,411 | |||
| Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss (unaudited, amounts in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenues: | |||||||||||||||
| Collaboration and license | $ | — | $ | — | $ | — | $ | 400 | |||||||
| Grant | — | 452 | 78 | 1,450 | |||||||||||
| Total revenues | — | 452 | 78 | 1,850 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 15,623 | 13,802 | 55,517 | 43,345 | |||||||||||
| General and administrative | 9,378 | 7,716 | 25,216 | 23,271 | |||||||||||
| Total operating expenses | 25,001 | 21,518 | 80,733 | 66,616 | |||||||||||
| Operating loss | (25,001 | ) | (21,066 | ) | (80,655 | ) | (64,766 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 1,202 | 1,548 | 3,331 | 5,311 | |||||||||||
| Interest expense | (1,991 | ) | — | (2,843 | ) | — | |||||||||
| Gain on change in fair value of warrant liability | 164 | 516 | 140 | 2,988 | |||||||||||
| Gain (loss) on change in fair value of derivative liability | 3,340 | — | (1,195 | ) | — | ||||||||||
| Gain (loss) on change in fair value of CVR liability | 10,700 | (16,900 | ) | 46,100 | 18,746 | ||||||||||
| Other income (expense), net | 114 | — | 237 | (5 | ) | ||||||||||
| Total other income (expense), net | 13,529 | (14,836 | ) | 45,770 | 27,040 | ||||||||||
| Net loss | $ | (11,472 | ) | $ | (35,902 | ) | $ | (34,885 | ) | $ | (37,726 | ) | |||
| Other comprehensive (loss) income: | |||||||||||||||
| Foreign currency translation adjustment | (13 | ) | (10 | ) | (45 | ) | 34 | ||||||||
| Total comprehensive loss | $ | (11,485 | ) | $ | (35,912 | ) | $ | (34,930 | ) | $ | (37,692 | ) | |||
| Net loss | $ | (11,472 | ) | $ | (35,902 | ) | (34,885 | ) | (37,726 | ) | |||||
| Net loss per share allocable to common stockholders: | |||||||||||||||
| Basic and diluted | $ | (0.38 | ) | $ | (1.38 | ) | $ | (1.21 | ) | $ | (1.45 | ) | |||
| Weighted-average common shares outstanding: | |||||||||||||||
| Basic and diluted | 30,309,295 | 26,002,892 | 28,894,967 | 25,962,302 | |||||||||||
Investor Contact
Megan LeDuc
Associate Director of Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Cartesian Therapeutics expect AURORA results and a Descartes-08 approval application?
Cartesian expects Phase 3 AURORA data in 1Q27 and plans a biologics license application in mid-2027. AURORA is evaluating Descartes-08 in patients with myasthenia gravis.
How long does Cartesian Therapeutics expect its cash to last?
Cartesian expects its $124.7 million in cash, cash equivalents and restricted cash at September 30, 2026 to support planned operations into 2028, including completion of the ongoing Phase 3 AURORA trial.
What is the primary endpoint of Cartesian Therapeutics’ AURORA trial?
AURORA will compare the proportion of Descartes-08 recipients achieving a three-point or greater improvement in the Myasthenia Gravis Activities of Daily Living score at Month 4 against placebo. The randomized, double-blind trial is designed for approximately 100 patients with acetylcholine receptor autoantibody-positive myasthenia gravis.
How was Descartes-08 retreatment timed in Cartesian Therapeutics’ myasthenia gravis analysis?
The five patients were retreated a median of 16.6 months after completing their initial Descartes-08 course. They had completed treatment in the Phase 2 portion of the trial, and their symptoms returned after 12 months of follow-up.